File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Treatment of Melanoma by a Novel Non-Viral Vector Mediated Delivery of Interleukin-2

TitleTreatment of Melanoma by a Novel Non-Viral Vector Mediated Delivery of Interleukin-2
Authors
Issue Date2009
PublisherAcademic Press,
Citation
American Society of Gene Therapy 12th Annual Meeting, San Diego, CA, 27-30 May 2009, In Molecular Therapy, 2009, v. 17 n. Supp 1, p. S222 Abstract no.582 How to Cite?
Abstracta cytokine showed the best anti-tumor activity in patients with malignant melanoma. However, the short half-life of IL-2 protein in serum requires repeated high doses, resulting in severe side effects. Here we reported a novel polycationnic vectors H1, which consists of low molecular weight polyethylenimine(PEI 600Da) linked by Cyclodextrin and conjugated with folate acid(named H1). We found that H1-mediated transfection of plasmid encoding IL-2(H1/IL-2) could suppress tumor growth and prolong survival of the melanoma tumor bearing mice. We showed that immune cells, including CTL and NK cells, play critical roles for antitumor effects of H1/IL-2. Importantly, the antitumor effects produced by repeated H1/IL-2 (50ug) injections were comparable to that of adenovirus carrying IL-2 (Adv-IL2, 2×108 pfu). Moreover, the numbers of CD4+CD25+ Treg cells in peripheral blood of the mice repeatedly injected with a high dose of H1/IL-2 were not augmented as compared with the control group. In conclusion, these results demonstrated that H1-mediated IL-2 plasmid transfection induces anti-tumor effects comparable to that of Adv-IL-2 with higher safety and thus represents an alternative gene therapeutic strategy for melanoma.
Persistent Identifierhttp://hdl.handle.net/10722/61670
ISSN
2015 SCImago Journal Rankings: 3.374

 

DC FieldValueLanguage
dc.contributor.authorYao, Hen_HK
dc.contributor.authorWang, Xen_HK
dc.contributor.authorNg, SMen_HK
dc.contributor.authorLin, MCen_HK
dc.date.accessioned2010-07-13T03:44:46Z-
dc.date.available2010-07-13T03:44:46Z-
dc.date.issued2009en_HK
dc.identifier.citationAmerican Society of Gene Therapy 12th Annual Meeting, San Diego, CA, 27-30 May 2009, In Molecular Therapy, 2009, v. 17 n. Supp 1, p. S222 Abstract no.582en_HK
dc.identifier.issn1525-0024-
dc.identifier.urihttp://hdl.handle.net/10722/61670-
dc.description.abstracta cytokine showed the best anti-tumor activity in patients with malignant melanoma. However, the short half-life of IL-2 protein in serum requires repeated high doses, resulting in severe side effects. Here we reported a novel polycationnic vectors H1, which consists of low molecular weight polyethylenimine(PEI 600Da) linked by Cyclodextrin and conjugated with folate acid(named H1). We found that H1-mediated transfection of plasmid encoding IL-2(H1/IL-2) could suppress tumor growth and prolong survival of the melanoma tumor bearing mice. We showed that immune cells, including CTL and NK cells, play critical roles for antitumor effects of H1/IL-2. Importantly, the antitumor effects produced by repeated H1/IL-2 (50ug) injections were comparable to that of adenovirus carrying IL-2 (Adv-IL2, 2×108 pfu). Moreover, the numbers of CD4+CD25+ Treg cells in peripheral blood of the mice repeatedly injected with a high dose of H1/IL-2 were not augmented as compared with the control group. In conclusion, these results demonstrated that H1-mediated IL-2 plasmid transfection induces anti-tumor effects comparable to that of Adv-IL-2 with higher safety and thus represents an alternative gene therapeutic strategy for melanoma.-
dc.languageengen_HK
dc.publisherAcademic Press,-
dc.relation.ispartofMolecular Therapy-
dc.titleTreatment of Melanoma by a Novel Non-Viral Vector Mediated Delivery of Interleukin-2en_HK
dc.typeConference_Paperen_HK
dc.identifier.emailWang, X: wangxc2005323@126.comen_HK
dc.identifier.emailNg, SM: ssmng@hku.hken_HK
dc.identifier.emailLin, MC: mcllin@HKUCC.hku.hken_HK
dc.identifier.authorityNg, SM=rp00767en_HK
dc.identifier.authorityLin, MC=rp00746en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038.mt.2009.106-
dc.identifier.hkuros157361en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats